NCT07126704View on ClinicalTrials.gov

A Phase 1, SAD and MAD to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral FB-101 in Healthy Adult Male Subjects

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2027

Conditions
Healthy
Interventions
DRUG

FB-101

FB-101 10mg

DRUG

Placebo for FB-101

Placebo for FB-101

Trial Locations (1)

03080

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

1ST Biotherapeutics, Inc.

INDUSTRY